

Sanofi to reimburse Philippines for unused dengue vaccine (Update)

January 15 2018

French pharmaceutical giant Sanofi will reimburse the Philippine government for leftover doses of an anti-dengue vaccine whose use was suspended due to health concerns, the two parties said Monday.

The manufacturer said the refund had nothing to do with safety issues and was meant to improve ties with the Philippine health department, which is investigating the deaths of more than a dozen children injected with Dengvaxia.

Philippine regulators stopped the sale and distribution of the drug last month after Sanofi warned that the injections could worsen the symptoms for vaccinated people who contracted the disease for the first time.

Health Secretary Francisco Duque told AFP he was scheduled to meet Sanofi representatives on Tuesday to discuss the refund, as well as a government demand that the company test all 837,000 Filipino children who were given the vaccine against dengue fever.

The health department said in a statement it had issued a "demand letter" to the company's vaccine unit Sanofi Pasteur to refund 1.4 billion pesos (\$27.8 million) for unused supplies of the drug.

"Our decision to reimburse for unused doses is not related to any safety or quality issue with Dengvaxia," said a statement from Sanofi Pasteur, which did not disclose the agreed amount.

"Rather Sanofi Pasteur hopes that this decision will allow us to be able to work more openly and constructively with the (health department) to address the negative tone towards the dengue vaccine in the Philippines today."

Philippine authorities have been investigating the deaths of 14 children who were among the students given Dengvaxia last year in the world's first public immunisation programme against dengue.

After the programme began, Sanofi Pasteur released findings in November of a new study which showed Dengvaxia could lead to severe infections in some cases.

The disclosure triggered a public furore, with some parents blaming the vaccine for their children's deaths and a number of legislators accusing the government of endangering public health.

Duque said he would ask Sanofi at Tuesday's meeting to provide testing kits to determine which of the injected Filipino children had no prior exposure to the disease.

"We have no choice. We've got to do that," he said of the testing, which he added would enable health authorities to have a more focused system to monitor the injected children.

Sanofi would be asked either to provide testing kits or finance the testing by an entity authorised by the health department, he added.

Duque said the test kits had been developed by Sanofi and the University of Pittsburgh to determine whether a person's immunity to the dengue virus was the result of vaccination or of a previous infection.

Sanofi Pasteur has maintained that no death has been found to have been

caused by Dengvaxia.

"Sanofi Pasteur strongly believes that this tone is due to a misunderstanding of the benefits and risks associated with the dengue vaccine," its statement said.

It cited "a lack of awareness amongst the general public, particularly parents of vaccinated children, that the overall benefit of dengue vaccination remains positive in high endemic countries like the Philippines".

© 2018 AFP

Citation: Sanofi to reimburse Philippines for unused dengue vaccine (Update) (2018, January 15) retrieved 2 May 2024 from

<https://medicalxpress.com/news/2018-01-sanofi-reimburse-philippines-unused-dengue.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.